Over the past fifteen years, Beijing TINAVI Medical Technologies Co., Ltd. (hereinafter referred to as “TINAVI”) has focused on the orthopedic field. Subject to the spirit of original research, TINAVI integrates the consciousness of innovation with design, R & D and manufacturing, and is dedicated to facilitating the development of accurate and intelligent orthopedic medicine.
TiRobot Orthopedic Robotic System, a core product of TINAVI, is capable to perform fracture surgeries on whole spine segment, pelvis and limbs, and may orient surgical instruments or implants with the assistance of robotic arm while used in combination with mobile X-ray diagnostic equipment (C-shaped X-ray machine). TiRobot is compatible to 2D and 3D modes, and features with entry points and intelligent algorithm for the calculation of trajectory. TiRobot makes traditional surgeries intelligent and complicated surgeries minimally invasive and accurate, and shows remarkable clinical advantages; and the realization of intelligent orthopedic surgery is promising in the future.
With priority given to the orthopedic robotic system, TINAVI has maintained the proportion of R & D investment over 30% for many years, which results in its leading technology. In this regard, TINAVI succeeded in developing the orthopedic surgery robot with proprietary intellectual property rights in China, and the performance indicator reached the level of international predicate products.
As a pioneer of Chinese medical robotics, TINAVI has obtained over 80 patents, and launched more than 20 key research projects at national, provincial and ministerial levels. Nowadays, it possesses the post-doctoral research station, and is the supporting institution of National & Local Joint Engineering Research Center of Medical Robots, the member of National Robotics Standardization General Group, the vice president unit of the Medical Robot Branch of Chinese Society of Biomedical Engineering (CSBME), the deputy director unit of the Beijing Intelligent Robot Industry Alliance and the director unit of the Zhongguancun Medical Device Industry Alliance.
By the end of 2019, TINAVI had employed 282 employees, among which there were 102 R & D personnel with proportion of 36.17%. As for the R & D Center subordinate to TINAVI, the R & D team has over 40 employees with doctoral degree or master degree, and has principal members coming from renowned universities both at home and abroad, scientific research institutes, famous hospitals and medical device manufacturers.
July 7, 2020 witnessed the successful listing of TINAVI in the STAR MARKET, which ushers in a new stage. It is not only the demand of the era, but also the mission of TINAVI to manufacture first-class products and become an internationally leading enterprise. On the strength of the capital market, TINAVI will continue its R & D and popularization of intelligent orthopedic surgical techniques, so as to energize doctors, benefit patients, achieve the autonomous and controllable high-end medical devices, and back up the healthy China strategy. Only in this way can TINAVI become an internationally leading enterprise of medical robotics, and fulfill its mission in the great era.
|Earnings Per Share||-0.08||-0.00||0.07|
|R&D expenditure as a % of operating revenue||33.55%||32.74%||30.42%|
|Total Owners' Equity||596.34||560.61||169.41|
|Net Cash Flows-Operating||20.53||13.15||5.73|
|Net Cash Flows-Investing||-147.08||-217.63||23.02|
|Net Cash Flows-Financing||-2.47||8.76||411.30|
|Name||No. of Shares Held (mn)||% of Shares Held|
All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.
Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.
Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.